Enlivex Therapeutics Ltd., a Nasdaq-listed immunotherapy company, has secured $21 million in debt financing to acquire an additional 3 billion RAIN tokens from the Rain Protocol prediction market platform. The company exercised an option to purchase the tokens at a 62% discount for $10 million on Sunday, March 24, 2026, and simultaneously extended its option to buy another 272.1 billion RAIN tokens at the same price until December 2027.
The debt financing was provided by The Lind Partners, a New York-based asset manager. Enlivex executive chair Shai Novik stated, "We are continuing to execute our prediction markets treasury strategy, and we are pleased that Lind provided us with substantial capital, allowing us to continue the execution of our operating plan, as well as to acquire approximately three billion additional RAIN tokens."
In a parallel move, Enlivex's board approved a separate $20 million share buyback program, creating a combined $41 million capital allocation strategy aimed at enhancing shareholder value while investing in the crypto ecosystem. The share repurchase is scheduled to execute over the next twelve months.
The value of Enlivex's RAIN treasury is intrinsically linked to the Rain Protocol's decentralized prediction market platform. The platform features a built-in 2.5% fee mechanism that automatically buys back and burns RAIN tokens, aiming to improve the token's supply-demand dynamics.
Following the announcement, the RAIN token initially rose 7% to $0.009 before settling at $0.0088, trading nearly flat with a 0.3% gain over 24 hours. Enlivex's own stock (ENVL) closed the trading day down 0.9% to $1.10 but gained 4.5% in after-hours trading to $1.15.
Rain Protocol operates on the Ethereum Layer-2 Arbitrum network and ranks among the top 10 prediction market platforms by total value locked (TVL) and fees over the past seven days. The broader prediction market sector has seen explosive growth, with trading volumes surging over 1,200% to $23.3 billion between February 2025 and February 2026, though the market remains dominated by Kalshi and Polymarket, which account for over 80% of volumes.
Enlivex, traditionally focused on developing cell therapy solutions for conditions like knee osteoarthritis, represents a growing trend of non-crypto companies purchasing digital assets to strengthen their balance sheets and attract a wider investor base. The company's investment highlights institutional interest in leveraging prediction markets for aggregating intelligence on complex outcomes, including potential applications for gauging clinical trial probabilities and regulatory timelines.
